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 ABSTRACT 
Cone snails, also known as marine gastropods, from Conus genus produce in their venom a diverse range of small 
pharmacologically active structured peptides called conotoxins. The cone snail venoms are widely unexplored 
arsenal of toxins with therapeutic and pharmacological potential, making them a treasure trove of ligands and 
peptidic drug leads. Conotoxins are small disulphide bonded peptides which act as remarkable selective inhibitors 
and modulators of ion channels (calcium, sodium, potassium), nicotinic acetylcholine receptors, noradrenaline 
transporters, N-methyl-D-aspartate receptors, and neurotensin receptors. They are highly potent and specific against 
several neuronal targets making them valuable as research tools, drug leads and even therapeutics. In this review we 
discuss their gene superfamily classification, nomenclature, post-translational modification, structural framework, 
pharmacology and medical applications of the active conopeptides. We aim to give an overview of their structure 
and therapeutic potential. Understanding these aspects of conopeptides will help in designing more specific peptidic 
analogues. 
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 INTRODUCTION 
Marine snails inhabit tropical coral reefs, around 700 species have been recognized and all are venomous. Deeper 
understanding of venom biology reveals that their toxin components have inherent exquisite selectivity which can be 
exploited both as magnificent pharmacological tools and as templates for rational drug design [1]. Conus venom is 
extremely rich in small, bioactive structured peptide toxins (conotoxins) which presumably evolved for rapid prey 
capture, defense, and competitor deterrence [2]. Conus species contain a large number of conopeptides and each 
species has venom with distinct pharmacological profile. Conotoxins are cysteine-rich-peptide based toxins 
containing multiple disulfide bridges. Each of these toxin serves as a highly specific ligand and has an exclusive 
molecular target which can be an ion channel, either voltage-gated or ion gated, and in few circumstances G-protein 
linked receptors. Conotoxins are used in both basic science research and therapeutic, as tools of investigations and 
also determining how specific receptors and ion channels work. 
This review focuses on conotoxin nomenclature, classification, post-translational modification, their three-
dimensional structure in native form and in complexes. The therapeutic and pharmacological applications of 
conotoxins have also been discussed. This compilation will help us to understand, how they display their selectivity 
& potency and will also hasten their progression into the clinic by supporting studies focused at designing more 
specific potent peptidic analogues. 
Nomenclature of Conopeptides 
The nomenclature of conopeptides was given by Cruz et al in 1985 [3] and was further modified by Gray et al in 
1988 [4]. The name of conopeptides start with the Greek alphabet that designates its pharmacological action, 
followed by a one- or two-letter code that indicates the Conus species from which the peptide is isolated, a Roman 
numerical specifying the cysteine arrangement of the peptide and a capital letter to signify a specific peptide variant 
which designates its superfamily. Conotoxin superfamilies are defined by their signal sequence in the initial pre- 
propeptide and the disulfide bond framework. Peptides belonging to same superfamily possess a highly conserved 
signal sequence and share a typical pattern of cysteine residues and a specific pharmacological function [5]. For 
instance, µ-Conotoxin GIIIA is a peptide which belongs to mu pharmacological family, has been isolated from 
Conus geographus and has a class III cysteine pattern grouped in superfamily A. Conopeptides which are novel and 
have unknown molecular target use a different convention [2]. It has species code in small letter, numerical 
designating the cysteine pattern and again a small alphabet indicating a particular variant. For instance, r11a is a 
peptide isolated from Conus radiates and has class XI cysteine pattern. 
Conopeptides which contain one or no disulfide bonds are named differently. They are named by combing a class 
name, followed by one- or two-letter code that designates the species. For example, conopressin-S, conotryphan-R 
and contulakin-G are from Conus striatus, Conus radiates and Conus geographus respectively. 
 
Classification of Conopeptides 
 
Conopeptides are toxins, present in the venoms of cone snails, which contain one or more disulfide bonds. Peptides 
with none or one disulfide bonds are disulfide-poor conopeptides and those having two or more disulfides are 
disulfide-rich conopeptides [6], also termed as conotoxins. It is suggested that a distinction of conopeptides on the 
basis of cysteine content and arrangement is not phylogenetically justified [7]. Conopeptides can be classified into 
following three categories on the basis of their signal sequence, cysteine pattern or framework and molecular target. 
 
Superfamilies 
Conopeptides are expressed as precursor protein, which are processed into mature peptides in endoplasmic reticulum 
and golgi apparatus. The characteristic organization of the initial precursor consists of ER signal sequence, followed 
by N-terminus pro-region, the mature peptide sequence and the C-terminus pro-region. During the maturation of 
protein precursor, the signal sequence and the N- and C-terminal pro-regions are cleaved to produce the final venom 
peptide. The degrees of conservation of these three regions show great variation. The signal sequence is most 
conserved while the pro-regions are diverse and the mature peptide being extremely variable. Based upon the 
similarity between the signal sequences of the precursors, conopeptides are classified into gene superfamilies, a 
classification system based on precursor signal peptide identity [8, 9]. Conotoxin precursor sequences are identified 
by targeted-cDNA sequencing and the advanced high-throughput transcriptome sequencing. 
Each superfamily has a well conserved signal sequence and is designated as capital letter, at the end, in conopeptide 
nomenclature. About 26 conopeptide superfamilies are known till date [10, 11]. Table 1 represents different type of 
conotoxin superfamilies, their mature peptide cysteine framework and the number of protein precursors for each 
superfamily. Several conopeptides did not cluster in any of the known superfamilies. These include contulakin and 
conantokin, which are cysteine-poor conopeptides and belong to superfamilies B and C respectively [7]. 
 
Structural families 
The presence of one or more disulfide bonds is the characteristic of conopeptides. Depending on the pattern of 
cysteine residues in the mature peptide region, conopeptides are grouped into structural families [10]. For example, a 
mature peptide can include a variable number of cysteines (4, 6, 8 or 10) and their respective position can vary. Six 
cysteines can be organized as CCC-C-C-C or CC-C-C-C-C or CC-C-C-CC where ‘-’ represents a variable number 
of amino acids. Table 2 represents different types of cysteine pattern, number of cysteines involved in each pattern 
and their cystine connectivities [10]. The disulfide bonding network, in addition to particular amino acids in inter-
cysteine loops, categorizes them [12]. 
 
Functional or Pharmacological families 
Conopeptides are classified into functional families, also known as pharmacological families, on the basis of their 
molecular targets and the physiological activity. They have been shown to target broad types of receptors, ion 
channels and transporters [13-15]. Each Conus species has venom with distinct pharmacological profile. There is a 
large array of different peptides in venoms, and each peptide has specificity for a particular receptor target. Table 3 
highlights 12 pharmacological families of conopeptides, their corresponding membrane receptor families and the 
peptide toxins that target these receptors [10]. 
 
Sequence of Conotoxins 
 
About 100-200 toxins are produced in the venom of each Conus species and there exists a remarkable 
hypervariability between the peptide sequences of different cone species. This sequence diversity is found both 
between the species as well as within the species [16-19]. Conotoxins are small peptides, mostly 10-40 amino acid 
residues in length. However the shortest conotoxin, conophanmus-V [20], has 8 amino acid residues and the longest 
conopeptide, con-ikot-ikot, is reported to have 86 amino acid residues [21]. The molecular weight of conopeptides 
ranges from 847 Da - 9445 Da and their isoelectric point shows variation, from very acidic to basic. They are 
disulfide rich peptides, which usually contain two or three disulfide bonds, providing substantial disulfide 
framework variation [22]. The first conopeptide to be sequenced and confirmed by chemical synthesis was α-
conotoxin-GIC. It belongs to Conus geographus and consists of 16 amino acid residues with two disulphide bonds 
[4, 23]. 
 
 
Post-translational modification 
 
Conopeptides show a high rate and variability of post-translational modifications (PTMs), which also accounts to an 
exceptional diversity exhibited by these peptides at inter and intra-species level. PTMs are the chemical or the 
structural changes brought in the amino acid residues of the peptide before forming the mature product. The process 
involves the participation of enzymes that change the nature of specific residues. The type of PTMs present in 
conopeptides involves disulfide-bridge formation; γ-carboxylation of glutamic acid; hydroxylation of valine at γ-
position, proline at C-4, and lysine at C-5; phosphorylation and sulfation of tyrosine; bromination of tryptophan at 
C-6; epimerization of L- to D-residues, like that of leucine, tryptophan, valine and phenylalanine; C-terminal 
amidation; N-terminal O-glycosylation and pyroglutamylation of threonine or serine [24, 25].  
Important and most prevalent PTMs in conopeptides are the disulfide bonds formation. The cross-linking between 
the cysteine side chains to form the disulfide bridges provides great stability to the three-dimensional conformation 
of the peptide. Conotoxins are encoded as protein precursors and the mature peptide is produced following the 
excision of N- and C- terminal regions of the precursor. Cleavage of C-terminal residues may result in an amidated 
C-terminus and similarly cleavage of N-termini of glutamine may result in formation of pyroglutamic acid amide 
from glutamic acid side chain and N-terminus. Besides, conotoxins also involve glycosylation which involves the 
attachment of carbohydrate group to the side chain of amino acid residues. They are reported to undergo O-linked 
glycosylation in which a carbohydrate group is attached to a hydroxyl group of serine, threonine or tyrosine amino 
acid residues of the peptide back bone. The first evidence for O-glycosylation in conopeptide was found in κA-
conotoxin SIVA using electrospray-mass spectrometry [26, 27] and the glycan moiety was identified to be 
Hex3HexNc2. Another example of O-linked glycosylation is observed in contulakin-G, which contains Hex-
HexNAc, SO4(HexNAc), Hex3 and Hex2HexNAc2 glycoform sequences identified using combination of MALDI-
TOF-MS, liquid secondary ion mass spectrometry (LSI-MS) and electrospray ionisation mass spectrometry (ESI-
MS).  
The details of the glycosylation pathway for conopeptides have not been outlined. But the literature suggests that O-
glycosylation initiates with the transfer of D-GalpNAc from UDP-α-D-GalpNAc to a Ser or Thr residue of the 
peptide backbone yielding α-D-GalpNAc-(1→O)-Ser/Thr [28, 29]. So far, no peptide target sequences for O-
glycosylation have been suggested, but the predominance of adjacent Pro and Ala residues have been correlated with 
the sites of O-glycosylation (NetOGlyc 3.1 Server). Although, the role of PTMs in conopeptides remain mostly 
unexplored. In general, the PTMs of amino acids extends the range of biological functions of the protein; for 
example, glycosylation helps in providing structural components, modifying physiological properties, mediating & 
modulating cell-adhesion and signaling [30, 31]. In case of conotoxins, the PTMs of amino acids increase the toxin 
potency [24, 25, 32, 33] and stabilize the three-dimensional structure of the peptide [34-36]. Thus, glycosylation 
may increase lifespan of peptides by stabilizing the structural conformation and slowing down its proteolytic 
degradation. 
 
Structure 
 
Till date, 134 structures of conotoxins have been deposited in Protein Data Bank. About 123 structures are 
determined by NMR method while only 11 structures are determined through X-ray crystallography. About 5 three 
dimensional crystal structures of native conotoxins are known, which belong to α- functional family. The other six 
crystal structures of conotoxins are in complex with their macromolecular targets. Conotoxins exhibit high structural 
diversity which is attributed to their large variation between the sequence of amino acid residues and cysteine 
framework. With few exceptions, conotoxins contain multiple disulfide bonds and the disulfide connection pattern 
plays an important role in defining their structure [22]. Conotoxins with similar cysteine framework can have 
different disulfide connectivity and may result in vastly different structures. For example, α- and χ- conotoxins share 
a similar framework of cysteine residues, but exhibit large structural differences due to their different disulfide 
connectivity.  α- conotoxins are dominated by helical structure while χ-conotoxins mainly contain β-sheet secondary 
structure. However, conopeptides having different number of disulfide bonds and significantly different sequences 
may share a common structural motif. For example, the three dimensional structure of MVIIA and RXIA contain a 
cysteine knot motif [37]. The cysteine knot is a protein motif containing three disulfide bridges, where two disulfide 
bonds with their backbone form a loop through which a third disulfide bond passes. This motif is found in 40% of 
known disulfide rich proteins [38] and provides structural stability to the protein. Despite having similar overall 
topology, the cysteine knot toxins may show some local structural and dynamic differences. For example, MVIIA 
and MrVIB which target different ion channels [39, 40] possess a cysteine knot motif. Both the peptide molecules 
have four inter-cystein loops, but for MrVIB one of the loops is disordered, contrary to MVIIA, that has well-
defined loops throughout. This disparity may be responsible for the functional variation found between the two 
peptide molecules.  
 
Folding 
 
The overall fold of conotoxins is known to be significantly influenced by their disulfide connectivity [41]. The 
folding of conopeptides is mainly determined by their cysteine framework and the spacing between the cysteine 
residues, while the final folding of the peptide involves non-covalent interactions among non-cysteine residues [33]. 
However, depending upon the significant variation in spacing between the cysteines, a conserved fold may or may 
not be formed [42]. From the three dimensional structures known so far, conotoxins can broadly have four structural 
backbone folds [13]. For example (as shown in Figure 1), in α-conotoxins, the formation of internal disulfide bonds 
bring N- and C-terminal ends of the peptide into close proximity of each other and folds the molecule to form a short 
helical segment. In µ-conotoxins, the peptide chain folds to form secondary structure elements comprising of a 
helical region and a β-hair pin, which are connected by loop structures. The structures of κ- and ω-conotoxins 
contain a triple stranded β-sheet and loop regions. Conantokins, which lack disulfide bridges, adopt a helical 
conformation [43].  
 
 
Three-dimensional structure of native Conotoxins  
 
Till date, 5 crystal structures of conotoxins, in their native state, are reported in Protein Data Bank (1HJE, 1A0M, 
1AKG, 1PEN & 1NOT). All the five structures, α-conotoxin SI from Conus striatus, α-conotoxin EpI from Conus 
episcopatus, α-conotoxin PnIB from Conus pennaceus, α-conotoxin PnIA from Conus pennaceus and α-conotoxin 
GI from Conus geographus belong to α-conotoxin family of conopeptides. 
 
PnIA and PnIB are 16 amino acid residue peptides which block the neuronal nicotinic acetylcholine receptor 
(nAChR). They have a α4/7 cysteine framework with two disulfide bonds formed between Cys2 - Cys8 and Cys3 -
Cys16. Their sequence comparison has shown that they differ at two positions, with Leu10 and Ser11 in PnIB 
replacing Ala10 and Asn11 of PnIA [42]. The overall structure of the two α-conotoxins are very similar to each 
other, showing a well superimposed backbone and similar side chains in most cases [42]. The largest differences 
observed in the main chain angles between the two α-conotoxins are ~20° for Pro13 and Tyr15. Their secondary 
structure elements consist of the α-helical region formed by two helical turns, a 310-helical turn and type I β turn 
towards the C-terminus of the peptide molecule. Apart from the two disulfide linkage, the molecules are stabilized 
by various intramolecular, intermolecular and water associated hydrogen bonds. Besides sharing similarities 
between sequence and structure, they have very similar shapes and surface charge distribution which is proposed to 
be responsible for their functional similarities as antagonists of neuronal nAChR.   
 
The structure of α-conotoxin GI has been elucidated by Guddat et al in 1996 [44]. It consists of 13 amino acid 
residues with two disulfide bonds formed between Cys2 - Cys7 and Cys3 –Cys13. It targets the muscle nAChR 
subtype and has a consensus sequence XCC-(H/N)PACGXX(Y/F)XC. The secondary structure elements consist of a 
single 310 helix followed by a type I β turn. The comparison of GI with PnIA & PnIB has shown significant 
differences in sequence, function, structure, shape and surface charge distribution. GI has α3/5 cysteine framework 
in contrast to PnIA & PnIB which have α4/7 sequence framework. The two inter-cysteine loops vary in length, with 
three & five residues in GI and five & seven amino acid residues in PnIA & PnIB. The comparison of their shapes 
has shown that G1 is triangular while PnIA & PnIB are rectangular. The overall net surface charge on GI is positive 
which is attributed to the presence of conserved lysine and arginine residues. However, in PnIA & PnIB lysine and 
arginine residues are absent and the only charged regions are the negatively charged Asp14 and the positively 
charged N-terminus of Gly1 so a net zero charge. This difference in the net electrostatic charge on α-conotoxins 
could play an important role in determining their specificity for neuronal and muscle nAChR [42]. 
 
The crystal structure of α-conotoxin EpI has been reported by Hu et al in 1998 [45]. The comparison of its structure 
with PnIA & PnIB has shown that it has a same α4/7 cysteine framework and loop size, and is selective to neuronal 
nAChR. However, EpI is known to block different mammalian neuronal subtype of nAChR, which is proposed to be 
due to the presence of charged residues, Asp5 & Arg7 in EpI unlike Leu5 & Pro7 in PnIA & PnIB. 
 
Three-dimensional structure of conotoxins in complexes 
 
Conotoxins are known to target diverse types of ion channels and receptors with strong affinity [5, 6, 46, 47]. 
Conotoxin subgroups, α-conotoxins, specifically bind to various subtypes of nAChRs with different affinities. α-
conotoxins PnIA has substantially higher affinity for α3β2 nAChR subtype [48] compared to α7-nAChR. Also, α-
conotoxins ImI is unique in its selectivity towards the neuronal α3β2 and α7-nAChR from fresh water snail Lymnaea 
stagnalis. The structural elucidation of conotoxins bound to their target receptor will provide the details of their 
binding interactions, which may potentially assist in the rational design using conotoxin scaffold leading to novel 
variants molecules with higher specificity and selectivity to various receptor subtypes. In general receptors are large 
membrane bound proteins unamenable for biophysical, structural and functional studies. Nevertheless, three-
dimensional crystal structures of six α-conotoxins in complex with nAChR homolog have been determined so far. 
Acetylcholine binding protein (AChBP) resembles most of the α7 subtypes of nAChR family and its ligand binding 
site contains all the conserved residues of nAChR receptors; making it a good model for their structural studies. 
 
The structure of α-conotoxins complexed with nAChBP revealed that the conopeptides molecules lie deep within the 
ligand binding site and they do not show any significant alteration in their conformation upon binding [49]. Their 
binding to AChBP is mainly dominated by hydrophobic interactions. In ImI complex, Arg7 and Trp10 are critical in 
the interaction with the ligand binding site unlike to the structure of PnIA & TxIA in complex with AChBP. The 
crystal structure of PnIA - AChBP complex shows that AChBP binds in an unselective manner [49] while TxIA 
reveals a 20° tilt in backbone due to the formation of salt bridge between Arg5 of TxIA and Asp195 of AChBP [50]. 
 
Conotoxin: pharmacological targets and applications 
Venom based peptides derived from venom of snakes, amphibians, insects, arachnids, marine cones, sea anemones 
and others are highly efficient in curing myriad of ailments and several are presently on the road to be developed 
into valuable potent drugs. Owing to their potential medical applications new peptides are identified on a regular 
basis. However, this is just like the tip of an iceberg where only few types of venom have been studied for potential 
therapeutic properties, and from these venoms few selected peptides studied in detail. Undoubtedly valuable 
unexplored venom peptides, in addition to previously unreported venomous animals, await discovery on land and 
sea. 
The biological effects exerted by any cone snail venom are the combined function of the physiological targets or 
receptors with which the individual toxin components bind. α-conotoxin peptides are important tools for 
discriminating between closely related nAChRs subtypes [15], whereas five among the seven drug target sites 
present on vertebrate voltage-gated sodium channels are defined by animal toxins [51]. Conopeptides exhibit 
antinociceptive, antiepileptic, neuroprotective or cardioprotective activities and thus have pharmacological 
applications in cancer, neuromuscular and psychiatric disorders (Figure 2). Conotoxins can be potentially used for 
pain therapeutics as they target the neuronal nAChR and thus have relevance in therapeutics of neurological diseases 
like alzheimer's disease, multiple sclerosis, diabetic neuropathy, shingles, and others [52, 53]. Numerous venom-
based antinociceptive agents are at various stages of development for therapeutic use. AVC1, isolated from an 
Australian cone species, Conus victoriae is highly effective in combating postsurgical and neuropathic pain, even 
speeding recovery post nerve injury. Conantokins have been shown to have efficacy in animal models of epilepsy 
[54]. Few companies commercializing conopeptides are Cognetix Inc., Metabolic Pharmaceuticals, Ltd., Elan Corp., 
Xenome, Ltd, and others. Several academic research centers worldwide are also participating in the preclinical 
development efforts. Selected therapeutic conopeptides with their commercial name and status are enlisted in Table 
4.  
The charm of targeting snail's venom for designing novel therapeutics lies in the exactitude and alacrity with which 
the various component peptides act; most of them target only a particular receptor class, excluding the rest. This 
indicates that they can generate a specific effect on the body's metabolic pathways nil side effects reliably and 
quickly; like instant reduction in heart rate or switching off the signaling of a particular class of nerve, for instance 
pain receptors. Presently, the known receptor targets of Conus peptides are broadly divided into following three 
classes: (a) ligand-gated ion channels; (b) voltage-gated ion channels; and (c) others. Hereby, we briefly discuss the 
therapeutic applications of the above three classes. 
 
Ligand-gated ion channels 
They are transmembrane protein channels that open to allow passage of ions in response to the binding of a chemical 
messenger (the ligand like neurotransmitters) to the protein, inducing a conformational transform in the protein 
molecule. Majority of the ligand-gated ion channel superfamily inhibitors are nicotinic acetylcholine receptor 
antagonists, with wide structural variations. α-conotoxins were the first characterized conopeptide which act upon 
nicotinic acetylcholine receptors at the neuromuscular junction as competitive antagonists. Conotoxins targeting 
nicotinic acetylcholine receptor are of two subtypes – neuromuscular (α-conotoxin GI, α-conotoxin MI, α-conotoxin 
EI, α-conotoxin PIVA, α-conotoxin EIVA, α-conotoxin OIVB, α-conotoxin PelVB and ψ-conotoxinPIIIE), and 
neuronal (α-conotoxin MII, α-conotoxin PIA, α-conotoxin ImII, α-conotoxin BuIA). σ-conotoxin GVIIIA target 
5HT3 receptors. In addition, conotoxins targeting glutamate receptors (NMDA subclass: conantokin-G and 
conantokin-L; AMPA subclass: con-ikot-ikot) are also known [55]. α-conotoxin Vc1.1 has been shown to alleviate 
pain associated with neuropathy and hasten recovery of injured neurons [56]. 
 
Voltage-gated ion channels 
They open or close in response to changes in the electric potential across a cell membrane. δ-conotoxins and µ-
conotoxin target voltage-gated sodium channels and κM-conotoxin peptides are voltage-gated potassium channel 
antagonists [55]. ω-conotoxins block specific voltage-gated calcium channels and are one of the well-studied 
conotoxins. Conotoxins that target sodium ion channels either hinder conductance (like the µ- and µO-conotoxins) 
or block channel inactivation (the δ-conotoxins). Conotoxins with differential specificity for certain sodium channel 
subtypes have been recently illustrated [57]. Conotoxins targeting voltage-gated potassium channels are structurally 
diverse: diverse groups of fish-hunting cone snails have conotoxins belonging to different families; all targeting a 
single subfamily of potassium channels, the Shaker (or Kvl) channels [58].  
 
In December 2004 the US Food and Drug Administration approved Ziconotide (Prialt
®
), a synthetic analog of ω-
conopeptide MVIIA for intrathecal targeted infusion with morphine for the treatment of severe chronic intractable 
pain [59]. Ziconotide is non-addictive and is isolated from the fish-hunting marine snail Conus magus also known as 
magician cone. As it can block N-type voltage-sensitive calcium channels in mammalian pain-sensing neurons and 
also causes tremors in mice, it is a powerful antinociceptive in circumstances where morphine is poorly or not 
active, rendering it as the best intrathecal analgesic drug available. Having a superb safety profile with no reported 
inflammation, neurotoxicity, mutagenicity, teratogenicity, or carcinogenicity, and low immunogenicity [59], it is 
being used for prevention of stroke and for refractory pain in patients suffering from AIDS or cancer who are 
tolerant to opioids [60]. 
 
Others 
Among the miscellaneous receptor targets which have been identified, the foremost are those affecting the G-protein 
coupled receptors (GPCRs). Some examples which can be cited are ρ-conotoxin TIA, conopressin (-G and –S), 
contulakin-G and conorfamide. ρ-conotoxin TIA were isolated from the fish-hunting Conus tulipa venom and was 
found to inhibit noradrenaline transporters and acted specifically on α1-adrenoceptors but not at all affected α2-
adrenoceptors, calcium or sodium channels, nicotinic acetylcholine or muscarinic receptors. ρ-conotoxin TIA has 
general disulfide bridge arrangement and tertiary folding pattern similar to α-conotoxins [61]. Norepinephrine 
transporter antagonists belonging to χ-conotoxin family (χ-conotoxin MrIA) are also reported [55]. χ-conopeptides 
(χ-MrIA and χ-MrIB) isolated from mollusk-hunting snail Conus marmoreus have been reported to bind to an 
allosteric site on the noradrenaline transporter and amplify the height of noradrenaline-induced contractions in rat 
vas deferens preparation [1, 61]. Additionally snail peptides may also target catecholamine transporters [61]. 
Additional classes of conopeptides were subsequently found to act at vasopressin receptors (conopressin) and 
neurotensin (neurotensin) receptors. 
  
FUTURE PERSPECTIVES 
 
The pharmacological diversity of the conopeptides have been underestimated, since the majority of the studies of the 
previous three decades focused on species that belong to only a few lineages, and several lineages remain largely 
understudied or even not studied at all [62]. Presently, detailed study of conotoxins is only in its infancy, suggesting 
a golden future for the discovery of new conotoxins and new therapeutic applications. Novel conotoxins based drug 
discovery requires concerted efforts of evolutionary biologists, taxonomists, molecular geneticists, neuroscientists, 
pharmacologists, structure biologists and toxicologists. The high-throughput bioassays integrated with advanced MS 
and next-generation sequencing methods are replacing the traditional assay-guided approach. 
The venom of every species of Conus is probably unique [47], but unfortunately, extinction threats pose danger of a 
potential loss of valuable vast source medical, scientific and commercial natural treasures. It was justly stated by 
Nobel Laureate (Peace) Eric Chivian - Center for Health and the Global Environment, Harvard Medical School in 
1985 “Cone snails may contain the largest and most clinically important pharmacopoeia of any genus in nature. To 
lose them would be a self-destructive act of unparalleled folly.” and extinction represents of source biota. With 
future development in peptidic drug delivery methods assisted with nanomedicine, effective oral conopeptides as 
drug pills can be anticipated.   
 
List of Abbreviations 
AChBP: acetylcholine binding protein  
nAChR: neuronal nicotinic acetylcholine receptor  
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FIGURES 
 
Fig 1: The three dimensional structure of Conotoxins showing four different structural backbone folds 
(reproduced with due permission and license from Adams et al, 1999, Drug Development Research, John 
Wiley and Sons) 
 Fig 2: Main pharmacological properties of conotoxins 
TABLES 
Table 1. Gene Superfamilies of conotoxins. 
Conotoxin	Superfamily	 Cysteine	Framework	 No.	of	Protein	
Precursors	
A	 I, II, IV, VI/VII, 
XIV, XXII	
276	
B1	 	 18	
B2	 VIII	 2	
B3	 XXIV	 1	
C	 	 4	
D	 XX	 28	
E	 XXII	 1	
F	 	 2	
G	 XIII	 1	
H	 VI/VII	 10	
I1	 VI/VII,	XI	 26	
I2	 XI,	XII,	XIV	 62	
I3	 VI/VII,	XI	 9	
J	 XIV	 30	
K	 XXIII	 4	
L	 XIV	 14	
M	 I,	II,	III,	IV,	VI/VII,	IX,	XIV,	XVI	 443	
N	 XV	 4	
O1	 I,	VI/VII,	IX,	XII,	XIV,	XVI	 575	
O2	 VI/VII,	XIV,	XV	 133	
O3	 VI/VII	 43	
P	 IX,	XIV	 12	
S	 VIII	 21	
T	 I,	V,	X,	XVI	 234	
V	 XV	 2	
Y	 XVII	 1	
	
	
		
	
	
	
	
	
Table 2. Cysteine framework pattern of conotoxins	
Cysteine	Pattern	 No.	of	Cysteine	in	each	
Pattern	
Cysteine	
Connectivity	
CC-C-C	 4	 I-III,	II-IV	
CCC-C-C-C	 6	 	
CC-C-C-CC	 6	 	
CC-C-C-C-C	 6	 I-V,	II-III,	IV-VI	
CC-CC	 4	 I-III,	II-IV	
C-C-CC-C-C	 6	 I-IV,	II-V,	III-VI	
C-C-C-C-C-C-C-C-C-C	 10	 	
C-C-C-C-C-C	 6	 I-IV,	II-V,	III-VI	
CC-C.[PO]C	 4	 I-IV,	II-III	
C-C-CC-CC-C-C	 8	 I-IV,	II-VI,	III-VII,V-VIII	
C-C-C-C-CC-C-C	 8	 	
C-C-C-CC-C-C-C	 8	 	
C-C-C-C	 4	 I-III,	II-IV	
C-C-CC-C-C-C-C	 8	 	
C-C-CC	 4	 	
C-C-C-CC-C	 8	 	
C-C-CC-CC	 6	 	
C-C-C-CCC-C-C-C-C	 10	 	
C-CC-C-CC-C-C-C-C	 10	 	
CC-C-C-C-CC-C-C-C	 10	 	
C-C-C-C-C-C-C-C	 8	 	
C-C-C-CC-C	 6	 	
C-CC-C	 4	 	
C-C-C-C-CC	 6	 	
C-C-C-C-CC-CC	 8	 	
 
	
		
	
	
	
	
	
Table 3:	Families of conopeptides with their corresponding pharmacological target membrane receptors 	
Pharmacological	Families	 Membrane	Receptor	Families	 Peptide	Toxins	
α	(alpha)	 Nicotinic	acetylcholine	receptors	(nAChR)	 GI	
γ	(gamma)	 Neuronal	pacemaker	cation	currents	
(inward	cation	current)	
PnVIIA,	TxVIIA	
δ	(delta)	 Voltage-gated	Na	channels	(agonist,	delay	
inactivation)		
TxVIA	
ε	(epsilon)	 Presynaptic	Ca	channel	or	G	protein-coupled	
presynaptic	receptors	
TxVA	
ι	(iota)	 Voltage-gated	Na	channels	(agonist,	no	
delayed	inactivation)	
RXIA	
κ	(kappa)	 Voltage-gated	K	channels	(blocker)	 PVIIA	
μ	(mu)	 Voltage-gated	Na	channels	(antagonist,	
blocker)	
GIIIA	
ρ	(rho)	 Alpha1-adrenoceptors	(GPCR)	 TIA	
σ	(sigma)	 Serotonin-gated	ion	channels	(GPCR)	 GVIIIA	
τ	(tau)	 Somatostatine	receptors	 CnVA	
χ	(chi)	 Neuronal	noradrenaline	transporter	 MrIA,	CMRVIA	
ω	(omega)	 Voltage-gated	Ca	channels	(blocker)	 GVIA	
 
 
 
 
 
 
  
 
 
 
 
Table 4. Preclinical and Clinical Development Efforts of Conopeptides based therapeutics  
Conopeptide Commercial 
Name 
Indication Molecular Target / 
Mechanism 
Clinical Stage 
ω-MVIIA Ziconotide, Prialt Intractable pain N-type calcium 
channels/blocker 
Phase IV (market, FDA 
approved) 
Contulakin-G CGX-1160 Neuropathic pain Neurotensin 
receptor/agonist 
Phase Ib (SCI -sciatica 
patients) 
ω-CVID AM-336 Neuropathic pain N-type calcium 
channels/blocker 
Phase IIa (cancer patients) 
Conantokin-G CGX-1007 Intractable 
epilepsy 
NMDA 
receptor/antagonist 
Phase I 
α-Vc1.1 ACV-1 Neuropathic pain Niconitic acetylcholine 
receptors/antagonist 
Phase II 
χ-MrIA Xen2174 Neuropathic pain Norepinephrine 
transporter/inhibitor 
Phase IIa (cancer patients) 
κ-PVIIA CGX-1051 Acute Myocardial 
Infarct, 
Cardioprotection 
K-channels/blocker Pre-clinical 
µO-MrVIB  
 
CGX-1002 Neuropathic pain Sodium channels/subtype 
selective blocker 
Pre-clinical 
µ-SIIIA  
 
PEG-SIIIA Inflammatory pain Sodium channels/blocker Pre-clinical 
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